Jorgen Elgqvist
Overview
Explore the profile of Jorgen Elgqvist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Timmermand O, Elgqvist J, Beattie K, Orbom A, Larsson E, Eriksson S, et al.
Theranostics
. 2019 Jun;
9(8):2129-2142.
PMID: 31149033
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the...
2.
Elgqvist J, Ahlberg D, Andersson H, Jensen H, Johansson B, Kahu H, et al.
World J Oncol
. 2017 Nov;
1(3):101-110.
PMID: 29147189
Background: The aim of this study was to investigate the therapeutic efficacy of advanced ovarian cancer in mice, using α-radioimmunotherapy with different high specific activities. The study was performed using...
3.
Elgqvist J
Int J Mol Sci
. 2017 May;
18(5).
PMID: 28531102
Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA...
4.
Ceder J, Elgqvist J
Front Oncol
. 2017 Jan;
6:273.
PMID: 28119854
Modern molecular and radiopharmaceutical development has brought the promise of tumor-selective delivery of antibody-drug conjugates to tumor cells for the diagnosis and treatment of primary and disseminated tumor disease. The...
5.
Timmermand O, Nilsson J, Strand S, Elgqvist J
Med Phys
. 2016 Dec;
43(12):6632.
PMID: 27908170
Purpose: The first main aim of this study was to illustrate the absorbed dose rate distribution from Lu in sections of xenografted prostate cancer (PCa) tumors using high resolution digital...
6.
Evans-Axelsson S, Timmermand O, Bjartell A, Strand S, Elgqvist J
Semin Nucl Med
. 2016 Feb;
46(2):165-79.
PMID: 26897720
Prostate cancer (PCa) is one of the most common cancers in men and is the second leading cause of cancer-related deaths in the USA. In the United States, it is...
7.
Elgqvist J, Timmermand O, Larsson E, Strand S
Anticancer Res
. 2016 Jan;
36(1):103-9.
PMID: 26722033
Aim: The purpose of the present study was to investigate the radiosensitivity of the prostate cancer cell lines LNCaP, DU145, and PC3 when irradiated with beta particles emitted from (177)Lu,...
8.
Nilsson J, Bauden M, Nilsson J, Strand S, Elgqvist J
Cancer Biother Radiopharm
. 2015 Nov;
30(9):386-94.
PMID: 26560194
An α-particle irradiator, enabling high-precision irradiation of cells for in vitro studies, has been constructed. The irradiation source was a (241)Am source, on which well inserts containing cancer cells growing...
9.
Elgqvist J, Frost S, Pouget J, Albertsson P
Front Oncol
. 2014 Jan;
3:324.
PMID: 24459634
This article presents a general discussion on what has been achieved so far and on the possible future developments of targeted alpha (α)-particle therapy (TAT). Clinical applications and potential benefits...
10.
Frost S, Back T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, et al.
Cancer Biother Radiopharm
. 2012 Dec;
28(2):108-14.
PMID: 23230896
Unlabelled: Abstract Purpose: Pretargeted radioimmunotherapy (PRIT) against intraperitoneal (i.p.) ovarian microtumors using avidin-conjugated monoclonal antibody MX35 (avidin-MX35) and (211)At-labeled, biotinylated, succinylated poly-l-lysine ((211)At-B-PLsuc) was compared with conventional radioimmunotherapy (RIT) using...